Free Trial
NASDAQ:PMCB

PharmaCyte Biotech (PMCB) Stock Price, News & Analysis

PharmaCyte Biotech logo
$1.23 +0.06 (+5.13%)
As of 05/2/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About PharmaCyte Biotech Stock (NASDAQ:PMCB)

Key Stats

Today's Range
$1.19
$1.30
50-Day Range
$1.13
$1.79
52-Week Range
$1.03
$2.42
Volume
10,380 shs
Average Volume
21,631 shs
Market Capitalization
$8.31 million
P/E Ratio
2.28
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

Receive PMCB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PharmaCyte Biotech and its competitors with MarketBeat's FREE daily newsletter.

PMCB Stock News Headlines

Gold Alert: The Truth About Fort Knox Is Coming
Owning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s already performing nearly twice as well as gold this year and looks ready to go much higher. If you wait for the news to hit, you’ll already be too late.
PharmaCyte Biotech Inc PMCB
PharmaCyte Biotech Invests In Femasys - Quick Facts
See More Headlines

PMCB Stock Analysis - Frequently Asked Questions

PharmaCyte Biotech's stock was trading at $1.57 on January 1st, 2025. Since then, PMCB stock has decreased by 22.9% and is now trading at $1.21.
View the best growth stocks for 2025 here
.

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) posted its earnings results on Monday, March, 17th. The company reported ($0.10) EPS for the quarter.

Shares of PMCB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PharmaCyte Biotech investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), ASML (ASML), GE Aerospace (GE), Oracle (ORCL) and Nokia Oyj (NOK).

Company Calendar

Last Earnings
3/17/2025
Today
5/04/2025
Fiscal Year End
4/30/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PMCB
Employees
4
Year Founded
N/A

Profitability

Trailing P/E Ratio
2.28
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$3.27 per share
Price / Book
0.37

Miscellaneous

Free Float
6,896,000
Market Cap
$8.31 million
Optionable
Optionable
Beta
-0.53
Free Today: Your Guide to Smarter Options Trades Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

This page (NASDAQ:PMCB) was last updated on 5/4/2025 by MarketBeat.com Staff
From Our Partners